rizatriptan has been researched along with Air Sickness in 3 studies
rizatriptan: structure given in first source; RN given refers to benzoate
| Excerpt | Relevance | Reference |
|---|---|---|
| "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation." | 9.15 | Rizatriptan reduces vestibular-induced motion sickness in migraineurs. ( Balaban, CD; Furman, JM; Marcus, DA, 2011) |
| "Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness." | 9.14 | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. ( Furman, JM; Marcus, DA, 2009) |
| "Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associated vestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibular battery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatment with either oral rizatriptan 10 mg or placebo." | 9.12 | Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. ( Furman, JM; Marcus, DA, 2006) |
| "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation." | 5.15 | Rizatriptan reduces vestibular-induced motion sickness in migraineurs. ( Balaban, CD; Furman, JM; Marcus, DA, 2011) |
| "Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness." | 5.14 | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. ( Furman, JM; Marcus, DA, 2009) |
| "Ten healthy adult migraineurs (5 migrainous vertigo and 5 migraine without associated vestibular symptoms) with a history of motion sickness were tested in three sessions: a baseline vestibular battery and two motion sickness provocation sessions two hours following randomly ordered blinded pre-treatment with either oral rizatriptan 10 mg or placebo." | 5.12 | Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. ( Furman, JM; Marcus, DA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furman, JM | 3 |
| Marcus, DA | 3 |
| Balaban, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs[NCT00360282] | 36 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Scores are based on a scale developed by Graybiel which rates seven subjective and objective signs of motion sickness. The total scores ranged from from 0 to 25. Zero indicating no motion sickness. Greater than 16 indicates severe motion sickness. Trials were stopped if scores were 16 or greater. Scores were taken before and after each rotation. (NCT00360282)
Timeframe: Pre and Post Stimulus (about 6 minutes apart)
| Intervention | units on a scale (Median) |
|---|---|
| Rizatriptan Visit | 5.1 |
| Placebo Visit | 9 |
Subjective report of distress ranging from 0 to 10 based on the method of Wolpe. Zero indicates no distress and 10 indicates severe distress. Measures used in this analysis match the times used in the analysis for Outcome 1. (NCT00360282)
Timeframe: Pre and Post Stimulus (6 minutes apart)
| Intervention | units on a scale (Median) |
|---|---|
| Rizatriptan Visit | 3 |
| Placebo Visit | 2 |
3 trials available for rizatriptan and Air Sickness
| Article | Year |
|---|---|
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs.
Topics: Adult; Double-Blind Method; Female; Humans; Migraine Disorders; Motion Sickness; Serotonin Receptor | 2009 |
Rizatriptan reduces vestibular-induced motion sickness in migraineurs.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Motion Sickness; | 2011 |
Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorder | 2006 |